Filtered By:
Source: Circulation
Condition: Bleeding
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 151 results found since Jan 2013.
Amplatzer ™ amulet™ left atrial appendage occluder versus watchman™ device for stroke prophylaxis (amulet ide): a randomized controlled trial
Conclusions: The Amulet occluder was non-inferior for safety and effectiveness of stroke prevention for NVAF compared with the Watchman device, and superior for LAA occlusion. Procedure-related complications were higher with the Amulet device and decreased with operator experience. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02879448.PMID:34459659 | DOI:10.1161/CIRCULATIONAHA.121.057063
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Dhanunjaya Lakkireddy David Thaler Christopher R Ellis Vijendra Swarup Lars Sondergaard John Carroll Michael R Gold James Hermiller Hans-Christoph Diener Boris Schmidt Lee MacDonald Moussa Mansour Brijeshwar Maini Laura O'Brien Stephan Windecker Amulet ID Source Type: research
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial
Conclusions: Rates of NACE and MACCE did not differ with abbreviated APT in high bleeding risk patients with or without an OAC indication and resulted in lower bleeding rates in patients without an OAC indication. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier:NCT03023020.PMID:34455849 | DOI:10.1161/CIRCULATIONAHA.121.056680
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Pieter C Smits Enrico Frigoli Jan Tijssen Peter J üni Pascal Vranckx Yukio Ozaki Marie-Claude Morice Bernard Chevalier Yoshinobu Onuma Stephan Windecker Pim A L Tonino Marco Roffi Maciej Lesiak Felix Mahfoud Jozef Bartunek David Hildick-Smith Antonio Col Source Type: research
Effect of Rivaroxaban and Aspirin in Patients with Peripheral Artery Disease Undergoing Surgical Revascularization: Insights from the VOYAGER PAD Trial
Conclusions: The efficacy of rivaroxaban is associated with a benefit in surgical LER patients. While bleeding was increased with rivaroxaban plus aspirin, the incidence was low, with no significant increase in fatal bleeding, intracranial hemorrhage or postprocedural bleeds requiring intervention. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02504216.PMID:34380322 | DOI:10.1161/CIRCULATIONAHA.121.054835
Source: Circulation - August 12, 2021 Category: Cardiology Authors: E Sebastian Debus Mark R Nehler Nicholas Govsyeyev Rupert M Bauersachs Sonia S Anand Manesh R Patel Fabrizio Fanelli Warren H Capell Taylor Brackin Franz Hinterreiter Dainis Krievins Patrice Nault Gabriele Piffaretti Alexei Svetlikov Nicole Jaeger Connie Source Type: research
A Composite Metric for Benchmarking Site Performance in TAVR: Results from the STS/ACC TVT Registry
Conclusions: There are substantial variations in the quality of TAVR care received in the United States, and 11% of sites were identified as providing care below the average level of performance. Further study is necessary to determine structural, process-related, and technical factors associated with high- and low-performing sites.PMID:33947202 | DOI:10.1161/CIRCULATIONAHA.120.051456
Source: Circulation - May 5, 2021 Category: Cardiology Authors: Nimesh D Desai Sean M O'Brien David J Cohen John Carroll Sreekanth Vemulapalli Suzanne V Arnold John K Forrest Vinod H Thourani Ajay J Kirtane Brian O'Neill Pratik Manandhar David M Shahian Vinay Badhwar Joseph E Bavaria Source Type: research
Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Conclusions: DAPT decreases the risk of recurrent stroke and composite events compared with monotherapy. DAPT increases the risk of major hemorrhage, except if the treatment is limited to 30 days and does not include the combination of aspirin plus ticagrelor.PMID:33926204 | DOI:10.1161/CIRCULATIONAHA.121.053782
Source: Circulation - April 30, 2021 Category: Cardiology Authors: Gabriela Trifan Philip B Gorelick Fernando D Testai Source Type: research
Biomarker-Based Risk Prediction With The ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation
Conclusions: The biomarker-based ABC-AF scores showed better discrimination than traditional risk scores and were recalibrated for precise risk estimation in patients not receiving oral anticoagulation. They can now provide improved decision support regarding treatment of an individual patient with AF.PMID:33849281 | DOI:10.1161/CIRCULATIONAHA.120.053100
Source: Circulation - April 14, 2021 Category: Cardiology Authors: Alexander P Benz Ziad Hijazi Johan Lindb äck Stuart J Connolly John W Eikelboom Jonas Oldgren Agneta Siegbahn Lars Wallentin Source Type: research
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: Despite many differences in baseline characteristics between women and men and higher baseline endogenous factor Xa levels in women, the intensity of anticoagulation achieved with edoxaban between the sexes was similar. Treatment with higher-dose edoxaban regimen resulted in an even greater reduction in hemorrhagic stroke and several serious bleeding outcomes in women than in men, whereas the efficacy profile was similar between sexes.
PMID: 33587659 [PubMed - as supplied by publisher]
Source: Circulation - February 16, 2021 Category: Cardiology Authors: Zelniker TA, Ardissino M, Andreotti F, O'Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA Tags: Circulation Source Type: research
Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial.
Conclusions: In patients with atrial fibrillation enrolled in CABANA who had clinically diagnosed stable heart failure at trial entry, catheter ablation produced clinically important improvements in survival, freedom from AF recurrence, and quality of life relative to drug therapy. These results, obtained in a cohort most of whom had preserved left ventricular function, require independent trial verification. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique Identifier: NCT00911508.
PMID: 33554614 [PubMed - as supplied by publisher]
Source: Circulation - February 8, 2021 Category: Cardiology Authors: Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL, Mark DB Tags: Circulation Source Type: research
